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Abstract: Peroxisome proliferator activated receptor α (PPARα) has the most relevant biological
functions among PPARs. Activation by drugs and dietary components lead to major metabolic
changes, from reduced triglyceridemia to improvement in the metabolic syndrome. Polymorphisms
of PPARα are of interest in order to improve our understanding of metabolic disorders associated with
a raised or reduced risk of diseases. PPARα polymorphisms are mainly characterized by two sequence
changes, L162V and V227A, with the latter occurring only in Eastern nations, and by numerous
SNPs (Single nucleotide polymorphisms) with a less clear biological role. The minor allele of L162V
associates with raised total cholesterol, LDL-C (low-density lipoprotein cholesterol), and triglycerides,
reduced HDL-C (high-density lipoprotein metabolism), and elevated lipoprotein (a). An increased
cardiovascular risk is not clear, whereas a raised risk of diabetes or of liver steatosis are not well
supported. The minor allele of the V227A polymorphism is instead linked to a reduction of steatosis
and raised γ-glutamyltranspeptidase levels in non-drinking Orientals, the latter being reduced in
drinkers. Lastly, the minor allele of rs4353747 is associated with a raised high-altitude appetite
loss. These and other associations indicate the predictive potential of PPARα polymorphisms for an
improved understanding of human disease, which also explain variability in the clinical response to
specific drug treatments or dietary approaches.
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1. Introduction
Metabolic disorders underlying an enhanced risk of cardiovascular disease (CVD), i.e., diabetes
and dyslipidemia, may be also associated with excess body weight, which frequently leads to the
metabolic syndrome (MetS) [1]. While reduction in low density lipoprotein cholesterol (LDL-C) still
remains a foremost target in cardiovascular (CV) prevention, low levels of high density lipoprotein
cholesterol (HDL-C) and elevated triglycerides (TG) play an important and independent role and have
become a major target of treatment [2]. Thus, the association between elevated small LDL, low HDL-C,
and high TGs bring about “atherogenic dyslipidemia,” which markedly raises CV risk and for which
different therapeutic strategies have been developed [3]. While treatment of hypercholesterolemia
can be successfully handled with drugs targeting cholesterol biosynthesis [4], MetS is characterized
by a number of diverse metabolic abnormalities that are more difficult to pursue. Control of the
metabolic syndrome and atherogenic dyslipidemia may be achieved by the agonists of the family of
peroxisome proliferator-activator receptors (PPARs), i.e., nuclear-hormone receptors and transcription
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factor activating ligands, discovered in the early 1990s [5], and potentially involved in the development
of CVD and metabolic disorders such as diabetes and inflammatory diseases [6].
The activation of the PPARs may lead to metabolic responses potentially altering homeostasis [7].
The family of PPARs is comprehensive of PPARα, PPAR β/δ, and PPARγ [8]. Each of these is codified
by different genes and shows overlapping interspecies sequences, particularly in the DNA binding
domain (DBD) and ligand binding domain (LBD). The structure of PPARs is quite similar for all
three members, and characterized by: (1) an N-terminal region, responsible for exerting activity and
achieving phosphorylation, (2) a DBD consisting of two Zinc-fingers, one on PPAR, and one on (retinoid
X receptor) RXR, with a linker region, (3) a flexible hinge region, (4) an LBD, and (5) the C-terminal
region [9].
Different PPARs are encoded by different chromosomes. PPARα is coded by chromosome
22q12-13.1, PPAR β/δ by chromosome 6p21.2-21.1, and PPARγ by chromosome 3p25.2 [10]. PPARs are
expressed in different tissues, α in liver, kidney, heart, muscle, and adipose tissue [11], β/δ in muscle,
brain adipose tissue and skin, γ is expressed in three forms: γ1-virtually in all tissues including heart,
muscle, colon, kidney, pancreas, and spleen, γ2 (30 amino acid longer than γ1) mainly in adipose tissue,
and γ3 in macrophages, large intestine, and white adipose tissue [12]. While the two latter PPARs
were identified at a later time, presenting close similarities and a limited scope of metabolic control
and potential treatment approaches, PPARα has been more extensively investigated and acts on a
wider range of metabolic steps, which are activated by a large number of agonists. For this purpose, by
using Pubmed.gov, we revised available English-language studies published from January 1990 to
August 2019 and relevant to the key clinical questions discussed in this review. Search terms included
PPARα polymorphisms, metabolic syndrome, diabetes, non-alcoholic fatty liver disease (NAFLD),
and atherosclerosis.
2. PPARα Expression and Function
PPARα expression is high in hepatocytes, enterocytes, and in vascular and immune cell types, such
as monocytes/macrophages, smooth muscle cells, endothelial cells, lymphocytes, and non-neuronal
CNS cells [13], i.e., microglia and astroglia [14]. All these cell types play a crucial role, particularly
in the case of the liver, in fatty acid oxidation, which provides energy to peripheral tissues [15]. The
lipid peroxisomal β-oxidation further occurs in brown adipose tissue and plays a potential role in
oxidant/antioxidant pathways [16].
The activation of PPARα, particularly by drugs or nutraceuticals, exerts a central role in lipid and
lipoprotein metabolism and may reduce the dyslipidemia associated with the MetS [17]. During the
fasting state, PPARα is activated by adipose tissue-derived fatty acids, which enhance the production
of ketone bodies through lipid oxidation in the liver and peripheral mononuclear cells [18]. The
mechanism of metabolic activation for PPARα is by way of a complex pathway, through the formation of
a heterodimer with the RXR. This determines a conformational change, which reflects gene transcription
or transactivation [19]. By this mechanism, the inhibited expression of nuclear factor KB (NF-kB) or
activator protein 1 responsible for inflammation [20] may take place. Interaction of activated PPARα
with response elements occurs by binding to a specific DNA sequence called PPAR Response Element
(PPRE), located upstream of the target gene, and by binding to another cofactor, which leads to an
active transcriptional complex followed by gene transcription [21].
The complexity of this translational mechanism involving phosphorylation, acetylation, and
ubiquitination, through the action of the c-Jun terminal kinase and (5’ AMP-activated protein kinase)
AMPK protein kinase 1 and 2, protein kinase A, and synthase kinase [22], makes the process
very vulnerable to any abnormality in DNA sequences, which makes evaluation of eventual SNPs
very significant.
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3. PPARα-Metabolic Effects and Identified Agonists
Activity of PPARα is mainly of a catabolic type, particularly activating oxidative mechanisms
leading to enhanced energy provision. Agonists of PPARα can be endogenous and synthetic.
Among endogenous activators are unsaturated fatty acids, eicosanoids [23], epoxyeicosatrienoic
acids, leukotriene B4, prostaglandins, and oleoylethanolamide (OEA) [24].
PPARα activators appear to belong to a general class of “fraudulent fatty acids,” i.e., agents that
do not undergo full mitochondrial catabolism. Instead, they need exposure to peroxisomes for their
complete catabolism [25]. These dietary and synthetic compounds frequently determine peroxisomal
proliferation, particularly in rodents, but not in higher species [26].
Synthetic drugs that can bind mainly to PPARα (in some cases, to multiple isoforms) belong again to
the fraudulent fatty acid series, particularly fibrates (fenofibrate, gemfibrozil, and bezafibrate), whereas
agents such as thiazolidinediones, e.g., pioglitazone and others, are mainly PPARγ activators [27].
Some agents such as saroglitazar are dual activators of PPARα and γ [28] and elafibranor of both
PPARα and β/δ [29,30]. Recently, very interesting natural compounds have been identified. Among
these, arjunolic acid, a triterpenoid saponin, isolated earlier from Terminalia arjuna and later from
Combretum nelsonii, Leandra chaeton, Cochlospermum tinctorium, and Cornus capitata is a powerful PPARα
activator shown to regress cardiac fibrosis by inhibiting non-canonical TFG-1β signaling [31].
The activity of PPARα in controlling uptake and catabolism of fatty acids plays a critical role in
generating fuel in the muscle and heart. It is mediated by the activation of mitochondrial carnitine
palmitoyl transferase I (CPT1) [32], and responsible for the transfer of activated fatty acids across the
mitochondrial outer membrane. In addition to fatty acid oxidation, the activity of PPARα includes a
rise of apolipoprotein (apo)A-I, apoA-II, and ATP binding cassette (ABC)A1, and of HDL-C. There is an
increase of very-low density lipoprotein (VLDL) clearance and activity of lipoprotein lipase (LPL) [33],
with a concomitant reduction of apoC-III, VLDL production, and an increase of LDL particle size. The
reduction of TGs and the increase of HDL after fibrates is fundamental in the management of the CV
risk in central obesity associated with insulin resistance, which leads to a potential improvement of
PPARα-related metabolic response [34].
Lastly, the development of the selective PPARα agonist, i.e., pemafibrate, offers a new dawn
in the approach to address the treatment gap related to atherogenic dyslipidemia. Pemafibrate
(formerly known as K-877) exhibits greatly enhanced PPARα potency and selectivity in cell-based
transactivation assays, being > 2500-fold more potent than fenofibric acid, the active metabolite of
fenofibrate, and > 5000-fold more specific for human PPARα than either PPARγ or δ [35].
4. Single Nucleotides Polymorphisms (SNPs)
SNPs, i.e., substitutions of a single nucleotide occurring at a specific position in the genome, are
not rare with PPARα and each variant can be present to an appreciable degree within a population (i.e.,
>1%) [36]. A number of major PPARα SNPs have been detected [37].
Among the most relevant SNPs, one codes for an amino acid change. The rs1800206 C > G (L162V)
is related to the involvement of PPARα in lipids and CV disease, being linked to the modulation of
PPARα gene expression. The frequent SNP rs4253778 G > C (intron 7 G/C) is, instead, linked to the
regulation of inflammation and oxidative stress [38].
The L162V polymorphism (rs1800206) is the only PPARα functional polymorphism found in the
Caucasian population. It is consequent to a C-to-G transversion, which determines a leucine-to-valine
substitution in the DNA binding domain of the human PPARα [39]. The transversion occurs at position
484 of exon 5 of the human PPARα gene, which encodes the second zinc finger of the DNA binding
domain, adjacent to a cysteine essential to the coordination for the Zn2+ atom of the second zinc finger
and immediately upstream of a region that determines the specificity and polarity of PPARα binding
to DNA [40]. The valine allele generally encodes for a more active PPARα, particularly in conditions of
high concentrations of a synthetic ligand [41].
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This polymorphism has important effects in dyslipidemia. The V162 minor allele is associated
with raised levels of total cholesterol, LDL-C, and triglycerides, thus leading to hyperlipidemia and
to an increased CV risk in whites. This is more likely in non-diabetics than in diabetics [42,43], with
the case being particularly strong in apoE4 carriers [44]. A gender difference was also noted in a
Lithuanian population in which the impact of the CG genotype on TG rise [Odds Ratio (OR) = 2.67,
95% CI 1.15–6.16] was found only in men [45]. In the Framingham Offspring Study, the V162 in males
was associated with significantly raised total and LDL-cholesterol and apo B levels. In females, a
similar trend was observed but only the apoB rise was statistically significant [46]. Similar findings, in
particular hyperapobetalipoproteinemia, in both genders, were reported in a Canadian study [43].
The 162Leu/Val genotype is more frequent in the German, Danish, Czech, and Brazilian population,
whereas the 162Val/Val is more frequent only in the Tunisian population [47]. It is possible to
demonstrate a much stronger association between this polymorphism (V162 allele), than the intron 7 G/C
polymorphisms with stage C heart failure. The minor allele induces a reduced myocardial expression
of long-chain 3-hydroxyacyl-CoA dehydrogenase and medium-chain acyl-CoA dehydrogenase [48]
(Table 1).
Table 1. Single nucleotide polymorphisms of PPARα, location, and their potential interaction with
biochemical findings.
SNP Biochemical and Pathological Changes
rs1800206 C > G (Leu162Val)
chr22:46218377 (GRCh38.p12)
Minor allele:
(1) Increased cardiovascular disease risk
Rise in: Total cholesterol, LDL-cholesterol, Triglycerides,
C-reactive protein, Lipoprotein (a) and Apolipoprotein C-III
Decrement in: HDL-cholesterol
(2) Uncertain impact on diabetes development
(3) No association with NAFLD
rs4253776 A > G (intron variant)
chr22:46233582 (GRCh38.p12) (1) Increased risk of diabetes
rs4253778 G > C (intron 7, G2528C)
chr22:46234737 (GRCh38.p12)
Minor allele:
(1) Increased cardiovascular risk factors
(2) Increased risk of ischemic heart disease
(3) Associated with the development of left ventricular
hypertrophy in response to exercise and hypertension
(4) Increased risk of diabetes
(5) Increased levels of Fetuin-A
rs1800234 T > C (Val227Ala)
chr22:46219983 (GRCh38.p12)
Minor allele:
(1) Reduced cholesterolemia and triglyceridemia, particularly
in women
(2) Influence on alcohol drinking habits
(3) Lower fat-related indexes
rs4253747 A > T (intron)
chr22:46217340 (GRCh38.p12)
(1) High altitude appetite loss, common symptom of acute
mountain sickness
The concentration of PPARα ligands influences the L162V polymorphism: V162 activity is almost
half the L162 activity when PPARα ligands are either absent or at low concentrations, but it rises much
more than the L162 if there are high concentrations of PPARα agonists [41]. This case could be of
interest in order to use polyunsaturated fatty acids or fibrates to treat left ventricular hypertrophy or
heart failure in V162 patients [49].
An association between the V162 allele and inflammation was reported by Caron-Duval in normal
Canadians [50]. Carriers of the minor allele exhibited increased C-reactive protein (CRP) values
after n-3 PUFA supplementation, vs a reduction in the L162 allele carriers, with no difference in
the hypotriglyceridemic response. High-sensitivity CRP (hs-CRP) represents a major biomarker of
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inflammation and associated risk in CVD. This elevation can be corrected by few lipid lowering
drugs [51,52]. This finding points out to a potentially elevated CV risk of the V162 carriers. Supporting
this tentative conclusion is the reported association between the V162 allele and triglyceridemia in a
large population sample in the United States [53]. V162 carriers has 78% higher TG levels with a 30%
lower HDL-C, with this single polymorphism accounting for 3.8% of the variation in triglyceridemia.
The additional effect of this polymorphism on adiposity points out to a potential impact on CV risk
(Table 1).
A further support to the axioma linking the L162V polymorphism to the CV inflammatory
burden is the detection, in a Chinese population, of an association between the minor V162 allele and
lipoprotein (a) (Lp(a)) levels [54]. Compared with LL carriers, significantly higher Lp(a) concentrations
were found in LV + VV individuals (mean difference: 49.07 mg/l, 95% CI 23.32–74.82 mg/l, p = 0.0002).
People with the V allele had overall significantly higher Lp(a) levels than those with the L allele.
Lp(a) likely contributes to CVD risk being more atherogenic than LDL since it contains both the
proatherogenic components of LDL and the oxidized phospholipids [55]. However, these findings
should be rated in the context of ethnic influences on the effects of the (L162V) variant. Shin et al.
reported an association between the variant and an intronic SNP in the PPARα with plasma levels of
apoC-III and TG in African-Americans versus no associations between these two SNPs and plasma
levels of apoC-III and TG in Caucasians [56]. ApoC-III has been proposed as a prominent negative
regulator of TG catabolism [57].
The effect of PPARα polymorphisms on diabetes is controversial. A post-hoc analysis of the
STOP-NIDDM Trial in which patients with impaired glucose tolerance were randomized to either
acarbose or placebo [58], reported that, in the placebo group, the G (V162) allele increased the risk of
diabetes by 93% (95% CI 1.05–3.58), which is a feature associated with elevated levels of plasma glucose
and insulin. Among patients allocated to the acarbose group, a higher diabetes risk was found in those
carrying the minor G allele of rs4253776 (OR: 1.73, 95% CI 1.04–2.88) and the CC genotype of rs4253778
(OR: 2.78, 95% CI 1.14–6.79) [59]. Flavell et al., after evaluating three gene polymorphisms (an A >
C variant in intron 1, the L162V variant, and the intron 7 G > C variant) and age at diagnosis in 912
Caucasian type 2 diabetic subjects, reported that the combination of the rare alleles of both the intron 1
A > C and intron 7 G > C variants synergistically lowered the age at diagnosis [60]. These findings
were not supported by Silbernagel et al., who reported instead no association between the L162V SNP,
type 2 diabetes, (body mass index) BMI, or body fat composition or liver fat content, concluding for
a lack of impact of L162V on the pathogenesis of type 2 diabetes or obesity [61] (Table 1). Similarly,
Sparsø et al. who genotyped the L162V polymorphism in the PPARα gene in 5,799 middle-aged white
people, did not detect any association of the minor allele with obesity or type 2 diabetes [62].
The rs4253778 polymorphism is characterized by a G-to-C transversion at nucleotide 2528 of
intron 7 in the human PPARα gene, in the noncoding region. Even if nonfunctional, it affects PPARα
transcriptional activity particularly in exercising and hypertensive subjects [49]. This polymorphism is
linked to CAD risk, which is in partial allelic association with the L162V variant, and it shows opposite
effects for CV risk [63]. The CC homozygotes show significantly higher total and LDL-cholesterol
levels, not accounting, however, for the raised CV risk [63]. Contrasting findings were reported in a
Brazilian case series of elderly individuals (mean 80 yo) where C carriers showed significantly lower
TG and VLDL levels and higher HDL-C [64]. The association of CAD risk and dyslipidemia with the
presence of the C allele was confirmed in an Indian population: the incidence of this polymorphism
in CAD patients was 17.3% against 6.7% in the control group [65]. This polymorphism has been
examined in a study on the progression of atherosclerosis in participants of the angiographic LOCAT
and Northwick Park Heart studies [66], which confirm the link between increased risk of ischemic heart
disease, progression of atherosclerosis, and C allele carrier status. In both of these studies, the V162 was
associated with a delayed progression. The C-allele carrier status also appears to be associated with the
development of left ventricular hypertrophy [49], especially in response to exercise and hypertension.
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Among patients who survived myocardial infarction, the carriers of the CC genotype showed higher
levels of fetuin-A [67], a hepatokine associated with an increased CV risk [68,69] (Table 1).
Another coding SNP (rs1800234) is located in the hinge region of the PPARα gene. It leads to
the sequence polymorphism Val227Ala. It is relatively frequent in the Oriental populations [70,71],
and essentially absent in the West. This variant attenuates the transcription of cytochrome P-450 4A6
(35–56%) and mitochondrial 3HMG-CoA synthase genes in the presence of fibrate ligands [72]. This
minor polymorphism is associated with reduced cholesterolemia and triglyceridemia, particularly in
women, and appears to be associated with alcohol drinking habits. In more than 5% of the Japanese
carriers, it appears to modify a response to alcohol. The A227 allele is associated with increased
γ-glutamyl transpeptidase activity in drinkers. In non-drinkers, the V227 polymorphism leads to
higher cholesterolemia, whereas, in drinkers, no significant lipid differences are found, which suggests
that the V227 variant influences PPARα activity specifically in non-drinkers [73].
The coding Val227Ala SNP may be implicated in the pathogenesis of NAFLD, the latter being
considered the hepatic manifestation of the MetS [74]. In 79 Chinese NAFLD patients and 63 healthy
controls, the minor A227 allele frequency was significantly different between NAFLD and control
subjects. A227 carriers had lower fat-related indexes, such as weight, BMI, hip circumference, waist
circumference, waist-to-hip ratio, and the percentage of body fat [75]. In 401 healthy Japanese subjects,
total cholesterol was lower in A227 carriers than in noncarriers, and the lipid profiles of A227 carriers
appeared favorable compared to non-carriers [70]. Since the Val227Ala variant is located in the region
between the DBD and LBD, which are also believed to contain the dimerization domain of the protein,
it has been hypothesized that the substitution of A for V at codon 227 may cause a functional change.
Consequently, the A227 isoform has higher activity than the V227 isoform [70], which potentially
explains the association with lower lipids and protection from steatosis development [76].
Apart from the case of the V227A polymorphism, the L162V SNP does not appear to be linked
to the risk of NAFLD. The frequency of this SNP in NAFLD was evaluated in 202 Italian subjects
compared to 346 healthy controls. No significantly different incidence was found between patients
and controls, but the V162 minor allele was associated with higher insulin resistance (IR) without
histological disease severity, which suggests that the risk related to increased IR may be balanced by
the protective effect of decreased oxidative stress, known as the other key player in the progression of
liver disease [77] (Table 1).
Other areas of human disease have been explored in order to assess a possible connection with
PPARα polymorphisms. The non-coding SNP rs4253747 appears to be associated with high altitude
appetite loss in Chinese young men, with the A allele specifically associated with an increase in
appetite loss (A vs T, OR = 1.79 95% CI = 1.08–2.95, p = 0.022). High altitude appetite loss is a common
symptom of acute mountain sickness [78], with a complex physiological and genetic regulation [79]. It
is hypothesized that the effect of PPARα on appetite could be mediated by the generation of OEA by
epithelial cells in the small intestine, after fatty acid ingestion [80].
5. Interaction between PPARα Polymorphisms and Diet on Plasma Lipoproteins
Environmental factors such as the diet may interact with the genetic background to modulate
metabolic parameters. The interaction between the L162V polymorphism and consumption of saturated
and polyunsaturated fatty acids (PUFA) appears to affect lipid responses. In 1,023 male and 1,103
female participants in the Framingham study, the V162 allele was associated with higher plasma TG
and apoC-III levels in subjects on a low PUFA diet (<6% of energy). The opposite was found when
the PUFA intake was higher, which indicates a significant dose-response relationship between PUFA
intake and TG concentrations, depending on the genotype [81]. In a study in healthy white men from
Quebec, the carriers of the V162 allele had lower total cholesterol and apoA-I concentrations after a
high PUFA diet [82] (Table 2).
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Table 2. Interaction between PPARα polymorphisms and diet on plasma lipoproteins.
SNP Lipid Changes
rs1800206 C > G (Leu162Val)
chr22:46218377 (GRCh38.p12)
(1) In 162V allele carriers, low PUFA diet was associated with
higher plasma TG and apoC-III levels. PUFA intake >8%
corresponded to a 4% lower plasma TG
(2) Lower total cholesterol and apoA-I upon a high PUFA diet
rs6008259 3′UTR G > A
(1) According to n-6 fatty acid intake (low vs. high consumers),
in carriers of GG or AG genotypes, high daily intake (>7.99 g/d)
of linoleic acid led to higher levels of total- and LDL-C
rs3892755 3′UTR C > T
(1) According to n-3 fatty acid intake (low vs. high consumers),
in carriers of CC or CT genotypes, high daily intake (>0.32 g/d)
of eicosapentaenoic acid + docosahexaenoic acid led to higher
levels of total- and LDL-C
There are, however, significant ethnic differences in the response to genetic variations in PPARα,
as demonstrated by the 3′ untranslated region (UTR) SNPs (rs6008259 and rs3892755). Among
participants from the ARIC (The Atherosclerosis Risk in Communities) study, these SNPs modulate the
association between lipids and dietary intake of n-6 fatty acid (in whites) and long-chain n-3 fatty acids
(in African Americans). Among those with this last heritage, carriers of either the PPARα 3′UTR CC or
CT genotypes, a larger intake of long-chain n-3 fatty acids (eicosapentaenoic acid + docosahexaenoic
acid) was associated with higher levels of total cholesterol and LDL-C. The same trend was found in
whites carrying either the PPARα 3′UTR GG or AG genotypes who consumed large amounts of n-6
fatty acids (>7.99 g/d). The opposite was found when the TT and AA genotypes were considered in
African-Americans and whites, respectively [83] (Table 2).
6. Impact of PPARα Polymorphisms on Fenofibrate Response
Changes in TG following fibrate treatment appear to be regulated by PPARα polymorphisms,
as shown in the Diabetes Atherosclerosis Intervention Study. Among type 2 diabetic patients given
fenofibrate, intron 7 G/G genotype (rs4253778) was more frequent in better responders (85% vs 69%).
The G/G homozygosity proved be a significant predictor of the TG response (OR: 3.10, 95% CI 1.28–7.52)
and, in those with raised baseline TG levels (>267 mg/dL), this SNP led to a relative reduction of
>30% after fenofibrate [84]. Effects of rare, potentially functional variants of PPARα were reported in
the GOLDN study (Genetics of Lipid Lowering Drugs and Diet Network) [85]. Of the 73 described
variants with an average of 4.8% minor allele frequency, 13 were found to be associated with a reduced
fenofibrate response (Table 3). In the group of extreme responders, carriers of at least one rare variant
showed a low TG response after three weeks of fenofibrate treatment, with no effects on HDL-C, LDL-C,
or inflammatory biomarkers, i.e., interleukin-6, interleukin-2, CRP, monocyte chemotactic protein-1, or
tumor necrosis factor-α [85]. Studies on the L162V polymorphism in patients with different types of
lipid disorders have failed to disclose any difference in response to fenofibrate treatment [34].
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Table 3. PPARα polymorphisms and difference in fenofibrate response.
SNP Lipid Changes
rs4253778 G > C (intron 7; G2528C)
chr22:46234737 (GRCh38.p12)
(1) In patients with type 2 diabetes, the intron 7 G/G
genotype was a significant predictor of TG response
(OR: 3.10, 95% CI 1.28–7.52)
13 rare variants (minor allele frequency < 1%):
- intronic variant 1 (35 base pairs upstream of exon 2)
- rs4253793 (5′–UTR, in the first half of exon 3)
- synonymous mutation (base pair location 44972983)
- rs1042311 (missense mutation (alanine to valine)
located in exon 7)
- The remaining nine of the 13 rare variants were
located in the 3′ UTR of PPAR. This region often
contains sequences targeted by microRNAs
(1) Decreased TG response after three weeks
of fenofibrate
7. PPARα in Environmental Reprogramming of Metabolism
PPARα activity is modulated by post-translational modifications including phosphorylation,
SUMOylation, ubiquitination, acetylation, and O-GlcNAcylation, that can be found at numerous
modification sites [86], and all have a direct impact on cellular metabolism and energy production.
PPARα, particularly in the liver, can be regulated by epigenetic modifications that can also induce
significant changes. The possible regulation of epigenetic inheritance systems by environmental
conditions may be crucial in the transfer of information to offspring [87].
Maternal diet, e.g., with protein restrictions throughout pregnancy, may lead to lower PPARα gene
methylation, which may result in a 10.5-fold higher expression in the liver of the offspring compared
to dams fed a control diet [88]. Epigenetic modifications on the specific expression pattern of PPARα
target genes may be detected when following the long term history of a patient, as well in the case of
heart failure patients, where changes in the direct methylation of DNA in the promoter region may
cause silencing, particularly in PPARα-regulated energy genes [89].
8. Conclusions
Studies on the role of PPARα in major human tissues and, particularly, in liver, have indicated
that mRNA expression is quite similar in humans and mice and may be reduced in severe hepatic
disorders, such as non-alcoholic steatohepatitis and hepatitis C. In human liver, PPARα plays a pivotal
role in various metabolic processes and its activation does not promote tumor formation, as found in
rodents. Therefore, PPARα activators hold full promise as therapy for patients with obesity and type 2
diabetes, but also for subjects with severe liver conditions, such as NAFLD.
The activity of PPARα appears to be linked to its genetic variants. SNPs, in most cases, are related
to non-coding variants with the exception of the L162V missense mutation in the Western regions
and hinge region mutation V227A mainly in the East. While the L162V appears to be best linked
to dyslipidemia, the hinge region mutation V227A appears to be more clearly linked to life habits
(alcohol) and to sex-linked lipid abnormalities.
The predictive potential of these polymorphisms is certainly of value in improving our
understanding of human disease, and also explaining variability in the clinical response to specific
drug treatments or dietary approaches.
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